

**Amendments of the Claims/Listing of Claims**

Please amend claims 1 and 34 as follows. This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently amended) An adhesive patch suitable for the transdermal administration of granisetron to a subject in need thereof, said patch comprising:  
  
an acrylic adhesive comprising:  
  
50 to 98% w/w of a primary acrylate monomer, and  
0.5 to 20% w/w of a monomer containing non-acidic hydroxyl moieties, and  
  
a physiologically effective amount of granisetron loaded in the **acrylic** adhesive,  
  
wherein the granisetron content of said patch remains substantially unchanged when stored at 25°C for **at least** six weeks.
2. (Previously presented) A patch according to claim 1, wherein the non-acidic hydroxyl moieties are provided by suitably selected comonomers.
3. (Previously presented) A patch according to claim 2, wherein the selected comonomers are selected from the group consisting of substituted acrylates and substituted methacrylates.
4. (Previously presented) A patch according to claim 3, wherein the acrylate is selected from the group consisting of hydroxymethyl acrylates, hydroxyethyl acrylates and hydroxypropyl acrylates.
5. (Previously presented) A patch according to claim 3, wherein the methacrylate is selected from the group consisting of hydroxymethyl methacrylates and hydroxyethyl methacrylates.

6. (Previously presented) A patch according to claim 1, which is pressure sensitive.
7. (Previously presented) A patch according to claim 1, containing 50 to 90% w/w of said primary acrylate monomer.
8. (Original) A patch according to claim 7, wherein the primary acrylate monomer is either 2-ethylhexyl acrylate or butyl acrylate.
9. (Previously presented) A patch according to claim 1, adapted to provide a pharmacologically effective amount of granisetron to said subject within about 2 hours after administration thereof.
10. (Previously presented) A patch according to claim 1, comprising up to about 10% by weight of granisetron.
11. (Previously presented) A patch according to claim 10, having less than 8% w/w granisetron.
12. (Previously presented) A patch according to claim 1, having a level of granisetron above 4% w/w.
13. (Previously presented) A patch according to claim 10, having a level of between 6% and 7.7% w/w of granisetron.
14. (Previously presented) A patch according to claim 1, wherein no crystallisation is observed after one month storage at room temperature and pressure.
15. (Previously presented) A patch according to claim 1, for the treatment and/or prophylaxis of chemically induced emesis.
16. (Previously presented) A patch according to claim 15, wherein the emesis is acute.

17. (Previously presented) A patch according to claim 15, wherein the emesis is delayed.

18. (Previously presented) A patch according to claim 1, for the treatment and/or prophylaxis of emesis associated with fractionated chemotherapy.

19. (Previously presented) A patch according to claim 1, for the treatment and/or prophylaxis of postoperative nausea and vomiting.

20. (Previously presented) A patch according to claim 1, for the treatment and/or prophylaxis of nausea and vomiting associated with radiotherapy.

21. (Previously presented) A patch according to claim 1, for the treatment and/or prophylaxis of nausea and vomiting associated with fractionated cancer therapy.

22. (Previously presented) A patch according to claim 1, for the treatment and/or prophylaxis of a condition selected from the group consisting of one or more of: pruritus, fibromyalgia and pain associated therewith, migraine, anxiety, cognitive and psychotic disorders, depression, schizophrenia, psychosis in postnatal depression, irritable bowel syndrome, alcoholism, obstructive sleep disturbed breathing, motion sickness, loss of cognitive function, urinary incontinence, dyskinesia, systemic lupus erythematosus, drug-induced pruritus, premature ejaculation, eating disorders, obsessive compulsive disorder, gastric motility disorders, chronic fatigue syndrome, dyspepsia and cocaine dependence.

23. (Previously presented) A patch according to claim 1, wherein the adhesive is loaded with between 3 and 12% w/w granisetron.

24. (Previously presented) A patch according to claim 23, wherein the adhesive is loaded with between 4 and 10% w/w granisetron.

25. (Previously presented) A patch according to claim 23, wherein the adhesive is loaded with between 5 and 8% w/w granisetron.

26. (Previously presented) A patch according to claim 1, incorporating no plasticizers or permeation enhancers.

27. (Cancelled)

28. (Previously presented) A patch according to claim 1, wherein, at an adhesive loading of 6% w/w of active granisetron, the adhesive has a surface area of between 10 and 100 cm<sup>2</sup>.

29. (Original) A patch according to claim 28, wherein the adhesive has a surface area of between 15 and 50 cm<sup>2</sup>.

30. (Previously presented) A method for the treatment and/or prophylaxis of a condition associated with 5-HT<sub>3</sub> receptor activity in a patient in need thereof, said method comprising applying an adhesive patch according to claim 1 to the skin of the patient.

31. (Previously presented) A method for the treatment and/or prophylaxis of chemotherapy induced nausea and vomiting in a patient in need thereof, said method comprising applying an adhesive patch according to claim 1 to the skin of the patient.

32. (Previously presented) A method for the treatment and/or prophylaxis of a patient having, or susceptible to, a condition selected from the group consisting of:

pruritus, fibromyalgia and pain associated therewith, migraine, anxiety, cognitive and psychotic disorders, depression, schizophrenia, psychosis in postnatal depression, irritable bowel syndrome, alcoholism, obstructive sleep disturbed breathing, motion sickness, loss of cognitive function, urinary incontinence, dyskinesia, systemic lupus erythematosus, drug-induced pruritus, premature ejaculation, eating disorders, obsessive compulsive disorder, gastric motility disorders, chronic fatigue syndrome, dyspepsia and cocaine dependence,

said method comprising applying an adhesive patch according to claim 1 to the skin of the patient.

33. (Previously presented) A patch according to claim 1, for the treatment and/or prophylaxis of chemotherapy-induced nausea and vomiting.

34. (Currently amended) A patch according to claim 1, wherein the granisetron content of said patch remains substantially unchanged when stored at 40°C for ~~at least~~ six weeks.